205 related articles for article (PubMed ID: 21513365)
1. How patient reporters identify adverse drug reactions: a qualitative study of reporting via the UK Yellow Card Scheme.
Krska J; Anderson C; Murphy E; Avery AJ
Drug Saf; 2011 May; 34(5):429-36. PubMed ID: 21513365
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
[TBL] [Abstract][Full Text] [Related]
3. Adverse drug reaction reporting in the UK: a retrospective observational comparison of yellow card reports submitted by patients and healthcare professionals.
McLernon DJ; Bond CM; Hannaford PC; Watson MC; Lee AJ; Hazell L; Avery A;
Drug Saf; 2010 Sep; 33(9):775-88. PubMed ID: 20701410
[TBL] [Abstract][Full Text] [Related]
4. Patient views and experiences of making adverse drug reaction reports to the Yellow Card Scheme in the UK.
McLernon DJ; Bond CM; Lee AJ; Watson MC; Hannaford PC; Fortnum H; Krska J; Anderson C; Murphy E; Avery A;
Pharmacoepidemiol Drug Saf; 2011 May; 20(5):523-31. PubMed ID: 21328634
[TBL] [Abstract][Full Text] [Related]
5. The importance of direct patient reporting of suspected adverse drug reactions: a patient perspective.
Anderson C; Krska J; Murphy E; Avery A;
Br J Clin Pharmacol; 2011 Nov; 72(5):806-22. PubMed ID: 21496066
[TBL] [Abstract][Full Text] [Related]
6. Nonmedical prescriber experiences of training and competence to report adverse drug reactions in the UK.
Thompson A; Randall C; Howard J; Barker C; Bowden D; Mooney P; Munyika A; Smith S; Pirmohamed M
J Clin Pharm Ther; 2019 Feb; 44(1):78-83. PubMed ID: 30206951
[TBL] [Abstract][Full Text] [Related]
7. Public awareness in Wales of the UK Yellow Card scheme for reporting suspected adverse drug reactions.
Bracchi RC; Tseliou F; Copeland L; Routledge PA; Thomas A; Woods F; Adams A; Walker J; Jadeja M; Atkinson MD; Ashfield-Watt P
Br J Clin Pharmacol; 2021 Aug; 87(8):3344-3348. PubMed ID: 33386761
[TBL] [Abstract][Full Text] [Related]
8. Identifying and managing adverse drug reactions: Qualitative analysis of patient reports to the UK yellow card scheme.
O' Donovan B; Rodgers RM; Cox AR; Krska J
Br J Clin Pharmacol; 2022 Jul; 88(7):3434-3446. PubMed ID: 35128732
[TBL] [Abstract][Full Text] [Related]
9. Adverse drug reaction reporting by community pharmacists-The barriers and facilitators.
Hughes ML; Weiss M
Pharmacoepidemiol Drug Saf; 2019 Dec; 28(12):1552-1559. PubMed ID: 31131966
[TBL] [Abstract][Full Text] [Related]
10. Assessing and further developing age-appropriate information for young people about reporting suspected adverse drug reactions.
Bioletti L; ; Woodward C; Jadeja M; Hawcutt DB
Br J Clin Pharmacol; 2024 Mar; 90(3):863-870. PubMed ID: 37990602
[TBL] [Abstract][Full Text] [Related]
11. Survey to assess public awareness of patient reporting of adverse drug reactions in Great Britain.
Fortnum H; Lee AJ; Rupnik B; Avery A;
J Clin Pharm Ther; 2012 Apr; 37(2):161-5. PubMed ID: 21592158
[TBL] [Abstract][Full Text] [Related]
12. Pharmacovigilance Reports Received from Children and Young People, and Development of Information to Aid Future Reporting from this Age Group.
Bhoombla N; Preston J; Ainsworth J; Bird H; Jadeja M; King C; Hawcutt DB
Paediatr Drugs; 2020 Jun; 22(3):335-341. PubMed ID: 32253722
[TBL] [Abstract][Full Text] [Related]
13. How do patients contribute to signal detection? : A retrospective analysis of spontaneous reporting of adverse drug reactions in the UK's Yellow Card Scheme.
Hazell L; Cornelius V; Hannaford P; Shakir S; Avery AJ;
Drug Saf; 2013 Mar; 36(3):199-206. PubMed ID: 23444232
[TBL] [Abstract][Full Text] [Related]
14. Views of British community pharmacists on direct patient reporting of adverse drug reactions (ADRs).
Krska J
Pharmacoepidemiol Drug Saf; 2013 Oct; 22(10):1130-3. PubMed ID: 22729956
[TBL] [Abstract][Full Text] [Related]
15. The contribution of Ghanaian patients to the reporting of adverse drug reactions: a quantitative and qualitative study.
Jacobs TG; Hilda Ampadu H; Hoekman J; Dodoo ANO; Mantel-Teeuwisse AK
BMC Public Health; 2018 Dec; 18(1):1384. PubMed ID: 30563498
[TBL] [Abstract][Full Text] [Related]
16. Public confidence in ADR identification and their views on ADRreporting: mixed methods study.
Jarernsiripornkul N; Patsuree A; Krska J
Eur J Clin Pharmacol; 2017 Feb; 73(2):223-231. PubMed ID: 27837337
[TBL] [Abstract][Full Text] [Related]
17. A patient's perspective: the impact of adverse drug reactions on patients and their views on reporting.
Lorimer S; Cox A; Langford NJ
J Clin Pharm Ther; 2012 Apr; 37(2):148-52. PubMed ID: 21592157
[TBL] [Abstract][Full Text] [Related]
18. Parental reporting of adverse drug reactions associated with attention-deficit hyperactivity disorder (ADHD) medications in children attending specialist paediatric clinics in the UK.
Tobaiqy M; Stewart D; Helms PJ; Williams J; Crum J; Steer C; McLay J
Drug Saf; 2011 Mar; 34(3):211-9. PubMed ID: 21332245
[TBL] [Abstract][Full Text] [Related]
19. Interpreting adverse drug reaction (ADR) reports as hospital patient safety incidents.
Davies EC; Green CF; Mottram DR; Pirmohamed M
Br J Clin Pharmacol; 2010 Jul; 70(1):102-8. PubMed ID: 20642552
[TBL] [Abstract][Full Text] [Related]
20. Adverse effects of neuromuscular blocking agents based on yellow card reporting in the U.K.: are there differences between males and females?
Light KP; Lovell AT; Butt H; Fauvel NJ; Holdcroft A
Pharmacoepidemiol Drug Saf; 2006 Mar; 15(3):151-60. PubMed ID: 16395661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
